Daily Stock Analysis, CARG, CARA THERAPEUTICS INC, priceseries

CARA THERAPEUTICS INC. Daily Stock Analysis
Stock Information
Open
23.56
Close
22.69
High
23.96
Low
22.69
Previous Close
23.63
Daily Price Gain
-0.94
YTD High
38.53
YTD High Date
Jan 21, 2020
YTD Low
14.25
YTD Low Date
Mar 18, 2020
YTD Price Change
-13.82
YTD Gain
-37.85%
52 Week High
40.91
52 Week High Date
Nov 20, 2019
52 Week Low
14.25
52 Week Low Date
Mar 18, 2020
52 Week Price Change
-7.58
52 Week Gain
-25.04%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 29. 2018
32.13
Jun 21. 2018
35.16
17 Trading Days
9.44%
Link
LONG
Jul 20. 2018
37.77
Aug 21. 2018
49.70
22 Trading Days
31.57%
Link
LONG
Sep 10. 2018
49.74
Oct 1. 2018
53.01
15 Trading Days
6.57%
Link
LONG
Jan 15. 2019
36.34
Feb 6. 2019
41.32
15 Trading Days
13.72%
Link
LONG
Nov 6. 2019
36.09
Dec 2. 2019
39.47
17 Trading Days
9.37%
Link
LONG
Apr 22. 2020
19.45
May 12. 2020
23.63
14 Trading Days
21.51%
Link
Company Information
Stock Symbol
CARG
Exchange
NASDAQ
Company URL
http://www.caratherapeutics.com
Company Phone
203-406-3700
CEO
Derek T. Chalmers
Headquarters
Connecticut
Business Address
4 STAMFORD PLAZA, 107 ELM STREET 9TH FLOOR, STAMFORD, CT 06902
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001346830
About

CARA Therapeutics, Inc. is a clinical-stage company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frédérique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Description

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The company's lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.